A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs SRT 2379 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 17 Feb 2012 Actual patient number chnaged from 34 to 39 according to ClinicalTrials.gov.
- 17 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2011 Actual initiation date (Aug 2011) added and official title amended as reported by ClinicalTrials.gov.